Announcements Trials
Browse Landscape

Phase

Phase 3 2

Status

Completed 1Active not recruiting 1

Sponsor Class

INDUSTRY 2

Study Type

Interventional 2

Sponsor

Cancer Type

CNS 1

Conditions

Breast Neoplasms 18Carcinoma, Renal Cell 8Neuroendocrine Tumors 6Tuberous Sclerosis 3Neoplasm Metastasis 3Kidney Neoplasms 3Triple Negative Breast Neoplasms 2Stomach Neoplasms 2Seizures 2Neoplasms 2Gastro-enteropancreatic neuroendocrine tumor 2Carcinoma 2Carcinoid Tumor 2Astrocytoma 2von Hippel-Lindau Disease 1Unilateral Breast Neoplasms 1Tuberous Sclerosis Complex-associated Refractory Seizures 1Tuberous Sclerosis 2 1Thymus Neoplasms 1Stomach Diseases 1Skin Neoplasms 1Renal Cell Cancer Metastatic 1Recurrence 1Prostatic Neoplasms 1Primary Non-metastatic Breast Cancer 1Polycystic Kidney, Autosomal Dominant 1Malignant Carcinoid Syndrome 1Lymphoma, Large B-Cell, Diffuse 1Lymphoma, B-Cell 1Lymphoma 1

Interventions

Cannabidiol 3Levetiracetam 2Everolimus 2Sodium Chloride 1Magnesium Sulfate 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Phase 3 × Seizures × Everolimus × Clear all
NCT02962414 2026-04-02

Roll-over Study to Collect and Assess Long-term Safety of Everolimus in Patients With TSC and Refractory Seizures Who Have Completed the EXIST-3 Study [CRAD001M2304] and Who Are Benefitting From Continued Treatment

Novartis

Phase 3 Active not recruiting
206 enrolled

Seizures, Tuberous Sclerosis

NCT00790400 2017-02-17

EXIST-2

Novartis

Phase 3 Completed
118 enrolled 15 charts
CNS

Tuberous Sclerosis 2, Astrocytoma, Hereditary Sensory and Autonomic Neuropathies, Seizures, Tuberous Sclerosis, Lymphangioleiomyomatosis, Angiomyolipoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡